Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Ophthalmology Physician in Middle River, MD
NPI: 1427255165Primary Practice Location
JOHNS HOPKINS HOSPITAL, THE
1800 Orleans St, Baltimore, MD
Primary Employer
Jhu - Wilmer Eye Institute
hopkinsmedicine.org
HQ Phone
Get M.D. Bryn's Phone Numberphone_androidMobile
Get M.D. Bryn's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
MD State Medical License
MD State Medical License
2011 - 2026
PA State Medical License
2007 - 2010
American Board of Ophthalmology
Ophthalmology
Johns Hopkins University
Residency • Ophthalmology
2008 - 2011
Perelman School of Medicine - Philadelphia
med.upenn.edu
Medical School
Until 2007
Albert Einstein Medical Center
Internship • Transitional Year
2007 - 2008
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 254 | 421 |
| 2 | 92014Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | 199 | 201 |
| 3 | 92134Diagnostic imaging of retina | 93 | 149 |
| 4 | 92133Diagnostic imaging of optic nerve of eye | 62 | 64 |
| 5 | 92083Measurement of field of vision during daylight conditions | 51 | 51 |
Authors: Burkholder, Bryn M, Dunn, James P
Journal: JAMA Ophthalmol
Vogt-Koyanagi-Harada disease
Authors: Bryn M. Burkholder
Publication Date: 2015-11
Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation.
Authors: Meghan Berkenstock, Jennifer Thorne
Publication Date: 2020-05-15
Lead Sponsor: JHSPH Center for Clinical Trials
Intervention / Treatment: BIOLOGICAL: Adalimumab (ADA), DRUG: Conventional immunosuppression (CON)
Lead Sponsor: Johns Hopkins University
Collaborators: Allergan
Intervention / Treatment: DRUG: Dexamethasone pellet
